Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low phenylalanine
Brand: PKU Sphere15, PKU Sphere20
PBAC's latest decision on Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low phenylalanine: Recommended (2017). Considered for Dietary management of phenylketonuria. The submission requested listing of a new sachet size (PKU Sphere15) and renaming of the existing product (PKU Sphere to PKU Sphere20).
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with phenylketonuria requiring dietary management via glycomacropeptide formula.
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Camino Pro Bettermilk and PKU Sphere
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.